Inflammatory cytokine network in schizophrenia

References

• Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, et al. 2008. Systematic metaanalyses and field synopsis of genetic association studies in schizophrenia: The SzGene database. Nat Genet 40:827–834.
   PubMed Web of Science ®Google Scholar
• Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Lopez-Rodriguez R, Fernandez-Navarro P, et al. 2011. ATA homozygosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. BMC Med Genet 12:81.
   PubMed Web of Science ®Google Scholar
• Anderson G, Maes M. 2013. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 42:5–19.
   PubMed Web of Science ®Google Scholar
• Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell’Osso B, et al. 2013. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42:1–4.
   PubMed Web of Science ®Google Scholar
• Arakelyan A, Zakharyan R, Khoyetsyan A, Poghosyan D, Aroutiounian R, Mrazek F, et al. 2011. Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia. BMC Clin Pathol 11:10.
   PubMedGoogle Scholar
• Arrode-Brusés G, Brusés JL. 2012. Maternal immune activation by poly(I:C) induces expression of cytokines IL-1β and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain. J Neuroinflammation 9:83.
   PubMed Web of Science ®Google Scholar
• Aston C, Jiang L, Sokolov BP. 2004. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 77:858–866.
   PubMed Web of Science ®Google Scholar
• Baker I, Masserano J, Wyatt RJ. 1996. Serum cytokine concen trations in patients with schizophrenia. Schizophr Res 20: 199–203.
   PubMed Web of Science ®Google Scholar
• Barak V, Barak Y, Levine J, Nisman B, Roisman I. 1995. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 6:61–69.
   PubMedGoogle Scholar
• Bauer K, Kornhuber J. 1987. Blood-cerebrospinal fluid barrier in schizophrenic patients. Eur Arch Psychiatry Neurol Sci 236:257–259.
   PubMedGoogle Scholar
• Bernstein HG, Steiner J, Bogerts B. 2009. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 9: 1059–1071.
   PubMed Web of Science ®Google Scholar
• Bessis A, Bechade C, Bernard D, Roumier A. 2007. Microglial control of neuronal death and synaptic properties. Glia 55: 233–238.
   PubMed Web of Science ®Google Scholar
• Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A. 1995. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38: 297–302.
   PubMed Web of Science ®Google Scholar
• Bitzer-Quintero OK, González-Burgos I. 2012. Immune system in the brain: a modulatory role on dendritic spine morphophysiology?Neural Plast 2012:348642.
   PubMed Web of Science ®Google Scholar
• Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M. 2001. Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 6:79–82.
   PubMed Web of Science ®Google Scholar
• Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, et al. 2012. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res 46:1421–1426.
   PubMed Web of Science ®Google Scholar
• Boyajyan A, Khoyetsyan A, Tsakanova G, Sim RB. 2008. Cryoglobulins as indicators of upregulated immune response in schizophrenia. Clin Biochemistry 41:355–360.
   PubMed Web of Science ®Google Scholar
• Boyajyan AS, Khoyetsyan AG, Chavushyan AS. 2010. Alternative complement pathway in schizophrenia. Neurochem Res 35: 894–898.
   PubMed Web of Science ®Google Scholar
• Boyajyan A, Zakharyan R, Khoyetsyan A. 2012. Chapter XI. Molecular and genetic indicators of aberrant immunity and apoptosis in schizophrenia In: Sumiyoshi T, editor. Schizophrenia research: Recent advances. Section II: Neuropsychobiological insights, Series: Mental Illnesses and Treatments. USA: Nova Science Publishers Inc. p. 183–240.
   Google Scholar
• Brites D, Fernandes A, Falcão AS, Gordo AC, Silva RF, Brito MA. 2009. Biological risks for neurological abnormalities associated with hyperbilirubinemia. J Perinatol 29 (Suppl 1):8–13.
   PubMedGoogle Scholar
• Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, et al. 2004. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 161:889–895.
   PubMed Web of Science ®Google Scholar
• Cazzullo CL, Saresella M, Roda K, Calvo MG, Bertrando P, Doria S, et al. 1998. Increased levels of CD8+ and CD4 + 45RA+ lymphocytes in schizophrenic patients. Schizophr Res 31:49–55.
   PubMed Web of Science ®Google Scholar
• Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Adorni A, Pegoraro M, et al. 2002. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 26:33–39.
   PubMed Web of Science ®Google Scholar
• Chavarria A, Alcocer-Varela J. 2004. Is damage in central nervous system due to inflammation?Autoimmun Rev 3:251–260.
   PubMed Web of Science ®Google Scholar
• Chen C, Tan B, Zhou Y, Zhou J, He Y, Li S, et al. 2012a. IL-28B genetic variant is associated with the risk of schizophrenia in the Chinese Han population. DNA Cell Biol 31:988–992.
   PubMed Web of Science ®Google Scholar
• Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, et al. 2012b. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmune Pharmacol 7:656–664.
   PubMed Web of Science ®Google Scholar
• Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, Vicenzi E, et al. 1998. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 12:1327–1332.
   PubMed Web of Science ®Google Scholar
• Crespo-Facorro B, Carrasco-Marín E, Pérez-Iglesias R, Pelayo-Terán JM, Fernandez-Prieto L, Leyva-Cobián F, et al. 2008. Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res 158:206–216.
   PubMed Web of Science ®Google Scholar
• Cross AK, Woodroofe MN. 2001. Immunoregulation of microglial functional properties. Microsc Res Tech 54:10–17.
   PubMed Web of Science ®Google Scholar
• Danis VA, Millington M, Hyland VJ, Grennan D. 1995. Cytokine production by normal human monocytes: Intersubject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 99:303–310.
   PubMed Web of Science ®Google Scholar
• Dean B. 2009. Is schizophrenia the price of human central nervous system complexity?Aust NZ J Psychiatry 43:13–24.
   PubMed Web of Science ®Google Scholar
• Dean OM, van den Buuse M, Bush AI, Copolov DL, Ng F, Dodd S, et al. 2009. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 16:2965–2976.
   PubMed Web of Science ®Google Scholar
• Debnath M, Mitra B, Bera NK, Chaudhuri TK, Zhang YP. 2013. Lack of association of IL-6 (-174 G/C) and TNF-α (-238 G/A) variants with paranoid schizophrenia in Indian Bengalee population. Cytokine 61:455–458.
   PubMed Web of Science ®Google Scholar
• Dennison U, McKernan D, Cryan J, Dinan T. 2012. Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychol Med 42:1865–1871.
   PubMed Web of Science ®Google Scholar
• Deverman BE, Patterson PH. 2009. Cytokines and CNS development. Neuron 64:61–78.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L, et al. 2013. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun 31:92 95.
   Web of Science ®Google Scholar
• Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. 2007. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93:261–265.
   PubMed Web of Science ®Google Scholar
• Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yang S, et al. 2013. C-reactive protein is elevated in schizophrenia. Schizophr Res 143:198–202.
   PubMed Web of Science ®Google Scholar
• Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. 2009. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 50: 1801–1807.
   PubMed Web of Science ®Google Scholar
• Drexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen L, Beumer W, Versnel MA, et al. 2010. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 10: 59–76.
   PubMed Web of Science ®Google Scholar
• Duan S, Xu Y, Chen W, Liu Z, Guo T, Gao J, et al. 2004. No association between the promoter variants of tumor necrosis factor alpha (TNF-alpha) and schizophrenia in Chinese Han population. Neurosci Lett 366:139–143.
   PubMed Web of Science ®Google Scholar
• Dunjic-Kostic B, Jasovic-Gasic M, Ivkovic M, Radonjic NV, Pantovic M, Damjanovic A, et al. 2013. Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatr Danub 25: 55–61.
   PubMed Web of Science ®Google Scholar
• Ebrinç S, Top C, Oncül O, Başoğlu C, Cavuşlu S, Cetin M. 2002. Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia. J Int Med Res 30:314–317.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Suddath RL, Wyatt RJ. 1993. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 17: 383–391.
   PubMed Web of Science ®Google Scholar
• Erbağci AB, Herken H, Köylüoglu O, Yilmaz N, Tarakçioglu M. 2001. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 10:109–115.
   PubMed Web of Science ®Google Scholar
• Fatjó-Vilas M, Pomarol-Clotet E, Salvador R, Monté GC, Gomar JJ, Sarró S, et al. 2012. Effect of the interleukin-1β gene on dorsolateral prefrontal cortex function in schizophrenia: a genetic neuroimaging study. Biol Psychiatry 72:758–765.
   PubMed Web of Science ®Google Scholar
• Fawzi MH, Fawzi MM, Fawzi MM, Said NS. 2011. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 190:91–97.
   PubMed Web of Science ®Google Scholar
• Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S, et al. 2004. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 25:1169–1173.
   PubMed Web of Science ®Google Scholar
• Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, et al. 2009. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 194:434–438.
   PubMed Web of Science ®Google Scholar
• Fila-Danilow A, Kucia K, Kowalczyk M, Owczarek A, Paul-Samojedny M, Borkowska P, et al. 2012. Association study of interleukin-4 polymorphisms with paranoid schizophrenia in the Polish population: a critical approach. Mol Biol Rep 39:7941–7947.
   PubMed Web of Science ®Google Scholar
• Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, et al. 2013. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18:206–214.
   PubMed Web of Science ®Google Scholar
• Francesconi LP, Ceresér KM, Mascarenhas R, Stertz L, Gama CS, Belmonte-de-Abreu P. 2011. Increased annexin-V and decreased TNF-α serum levels in chronic-medicated patients with schizophrenia. Neurosci Lett 502:143–146.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Brockman MA, Henderson DC, Evins AE, Fan X, Walsh JP, et al. 2010. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res 176:99–102.
   PubMed Web of Science ®Google Scholar
• Frommberger UH, Bauer J, Haselbauer P, Fräulin A, Riemann D, Berger M. 1997. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247:228–233.
   PubMed Web of Science ®Google Scholar
• Gaillard JM, Tissot R. 1979. Blood-brain movements of tryptophan and tyrosine in manic-depressive illness and schizophrenia. J Neural Transm Suppl 15:189–196.
   Google Scholar
• Ganguli R, Rabin BS, Belle SH. 1989. Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 26: 427–430.
   PubMed Web of Science ®Google Scholar
• Ganguli R, Brar JS, Solomon W, Chengappa KN, Rabin BS. 1992. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 44:113–123.
   PubMed Web of Science ®Google Scholar
• Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, Rabin BS. 1994. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51:1–10.
   PubMed Web of Science ®Google Scholar
• Gattaz WF, Dalgalarrondo P, Schröder HC. 1992. Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected. Schizophr Res 6:237–241.
   PubMed Web of Science ®Google Scholar
• Hacker UT, Erhardt S, Tschöp K, Jelinek T, Endes S. 2001. Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1b after live yellow fever vaccination. Clin Exp Immunol 125:465–469.
   PubMed Web of Science ®Google Scholar
• Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98:4746–4751.
   PubMed Web of Science ®Google Scholar
• Hakobyan SS. 2005. Immune complexes and classical pathway of complement activation in schizophrenia. PhD thesis in biological sciences (molecular and cellular biology, 03.00.03; immunology, 03.00.06), Yerevan.
   Google Scholar
• Hakobyan S, Boyajyan A, Sim RB. 2005. Classical pathway complement activity in schizophrenia. Neurosci Lett 374: 35–37.
   PubMed Web of Science ®Google Scholar
• Hänninen K, Katila H, Saarela M, Rontu R, Mattila KM, Fan M, et al. 2008. Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci 258: 10–15.
   PubMed Web of Science ®Google Scholar
• Hanson DR, Gottesman II. 2005. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 6:7.
   PubMed Web of Science ®Google Scholar
• Haroutunian V, Katsel P, Dracheva S, Stewart DG, Davis KL. 2007. Variations in oligodendrocyte-related gene expression across multiple cortical regions: Implications for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol 10:565–573.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Schönherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U. 2011. Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 45:1358–1365.
   PubMed Web of Science ®Google Scholar
• Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, et al. 2009. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 11:726–734.
   PubMed Web of Science ®Google Scholar
• Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. 2011. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 45:1608–1616.
   PubMed Web of Science ®Google Scholar
• Huang HH, Wang YC, Wu CL, Hong CJ, Bai YM, Tsai SJ, et al. 2011. TNF-α -308 G> A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neurosci Lett 504: 277–280.
   PubMed Web of Science ®Google Scholar
• Hulkkonen J, Laippala P, Hurme M. 2000. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1b plasma levels in healthy individuals. Eur Cytokine Netw 11:251–255.
   PubMed Web of Science ®Google Scholar
• Hurme M, Santtila S. 1998. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1b genes. Eur J Immunol 28:2598–2602.
   PubMed Web of Science ®Google Scholar
• Igue R, Potvin S, Bah R, Stip E, Bouchard RH, Lipp O, et al. 2011. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 35:1695–1698.
   PubMed Web of Science ®Google Scholar
• Ishizuka K, Kimura T, Igata R, Katsuragi S, Takamatsu J, Miyakawa T. 1997. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci 51:135–138.
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Kato T. 2006. Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist 12: 349–361.
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T, et al. 2005. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci 25:5376–5381.
   PubMed Web of Science ®Google Scholar
• Jarskog LF. 2006. Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations. Curr Opin Psychiatry 19: 307–312.
   PubMed Web of Science ®Google Scholar
• John GR, Lee SC, Brosnan CF. 2003. Cytokines: powerful regulators of glial cell activation. Neuroscientist 9:10–22.
   PubMed Web of Science ®Google Scholar
• Jonakait GM. 1996. Cytokines in neuronal development. Adv Pharmacol 37:35–36.
   Google Scholar
• Jun TY, Lee KU, Pae CU, Chae JH, Bahk WM, Kim KS, Han H. 2003. Polymorphisms of interleukin-4 promoter and receptor gene for schizophrenia in the Korean population. Psychiatry Clin Neurosci 57:283–288.
   PubMed Web of Science ®Google Scholar
• Kamińska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szerszeń M. 2001. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 49:439–445.
   PubMed Web of Science ®Google Scholar
• Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, et al. 2005. Interaction of tumor necrosis alpha - G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 255:279–283.
   PubMed Web of Science ®Google Scholar
• Katila H, Appelberg B, Hurme M, Rimón R. 1994a. Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res 12: 29–34.
   PubMed Web of Science ®Google Scholar
• Katila H, Hurme M, Wahlbeck K, Appelberg B, Rimón R. 1994b. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology 30:20–23.
   PubMed Web of Science ®Google Scholar
• Katila H, Hänninen K, Hurme M. 1999. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 4:179–181.
   PubMed Web of Science ®Google Scholar
• Kato T, Monji A, Hashioka S, Kanba S. 2007. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr Res 92:108–115.
   PubMed Web of Science ®Google Scholar
• Kato TA, Monji A, Mizoguchi Y, Hashioka S, Horikawa H, Seki Y, et al. 2011. Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a ‘fire extinguisher’ in the brain of schizophrenia?Mini Rev Med Chem 11:565–574.
   PubMed Web of Science ®Google Scholar
• Khandaker GM, Zimbron J, Lewis G, Jones PB. 2012. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med 16:1–19.
   Google Scholar
• Khoyetsyan A, Boyajyan A, Melkumova M. 2007. Level and chemical composition of cryoglobulins in schizophrenia. In: Brilliant Light in Life and Material Sciences. NATO Security through Science Series. Netherlands: Springer. p. 295–298.
   Google Scholar
• Khoyetsyan A, Boyajyan A, Tsakanova G, Sim RB. 2008. Abnormal immune complexes in schizophrenia. Neurochem J 2:329–330.
   Google Scholar
• Kim YK, Lee MS, Suh KY. 1998. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 43:701–704.
   PubMed Web of Science ®Google Scholar
• Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. 2009. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology 59:123–129.
   PubMed Web of Science ®Google Scholar
• Kinney DK, Hintz K, Shearer EM, Barch DH, Riffin C, Whitley K, et al. 2010. A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazars, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Med Hypotheses 74: 555–563.
   PubMed Web of Science ®Google Scholar
• Kowalski J, Blada P, Kucia K, Madej A, Herman ZS. 2001. Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res 50:169–175.
   PubMed Web of Science ®Google Scholar
• Kraft AD, Harry GJ. 2011. Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 8:2980–3018.
   PubMed Web of Science ®Google Scholar
• Kubistova A, Horacek J, Novak T. 2012. Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub 24(Suppl 1): 153–156.
   Web of Science ®Google Scholar
• Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. 2011. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 33:268–274.
   PubMed Web of Science ®Google Scholar
• Kushner I. 1993. Regulation of the acute phase response by cytokines. Perspect Biol Med 36:611–622.
   PubMed Web of Science ®Google Scholar
• Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. 1993. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 150:1408–1410.
   PubMed Web of Science ®Google Scholar
• Lin CC, Chang CM, Chang PY, Huang TL. 2011. Increased interleukin-6 level in Taiwanese schizophrenic patients. Chang Gung Med J 34:375–81.
   PubMedGoogle Scholar
• Liu J, Liu J, Zhou Y, Li S, Li Y, Song X, et al. 2011. Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population. DNA Cell Biol 30:913–917.
   PubMed Web of Science ®Google Scholar
• Liu L, Jia FJ, Li HF. 2007. The mRNA expression levels of IL-1beta, TNF-alpha and tyrosine hydroxylase in peripheral blood of paranoid schizophrenic patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23:1043–1105.
   PubMedGoogle Scholar
• Liu L, Jia F, Yuan G, Chen Z, Yao J, Li H, Fang C. 2010. Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. Psychiatry Res 176:1–7.
   PubMed Web of Science ®Google Scholar
• Löffler S, Klimke A, Kronenwett R, Kobbe G, Haas R, Fehsel K. 2010. Clozapine mobilizes CD34 + hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J Clin Psychopharmacol 30:591–595.
   PubMed Web of Science ®Google Scholar
• Looney JM, Childs HM. 1934. The lactic acid and glutathione content of the blood of schizophrenic patients. J Clin Invest 13:963–968.
   PubMedGoogle Scholar
• Maes M, Meltzer HY, Bosmans E. 1994. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89:346–351.
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. 1995a. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29:141–152.
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Buckley P, Bosmans E. 1995b. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244:325–329.
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M, et al. 1996. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 21:39–50.
   PubMed Web of Science ®Google Scholar
• Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, et al. 1997. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 66:1–11.
   PubMed Web of Science ®Google Scholar
• Maric NP, Svrakic DM. 2012. Why schizophrenia genetics needs epigenetics: a review. Psychiatr Danub 24:2–18.
   PubMed Web of Science ®Google Scholar
• Mayilyan KR. 2012. Complement genetics, deficiencies, and disease associations. Protein Cell 3:487–496.
   PubMed Web of Science ®Google Scholar
• Mayilyan KR, Arnold JN, Presanis JS, Soghoyan AF, Sim RB. 2006. Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neurosci Lett 404: 336–341.
   PubMed Web of Science ®Google Scholar
• Mayilyan KR, Dodds AW, Boyajyan AS, Soghoyan AF, Sim RB. 2008a. Complement C4B protein in schizophrenia. World J Biol Psychiatry 9:225–230.
   PubMed Web of Science ®Google Scholar
• Mayilyan KR, Weinberger DR, Sim RB. 2008b. The complement system in schizophrenia. Drug News Perspect 21(4): 200–210.
   PubMedGoogle Scholar
• McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al. 1995. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 152:1291–1297.
   PubMed Web of Science ®Google Scholar
• McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr, et al. 2005. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 112:1113–1120.
   PubMed Web of Science ®Google Scholar
• Meisenzahl EM, Rujescu D, Kirner A, Giegling I, Kathmann N, Leinsinger G, et al. 2001. Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am J Psychiatry 158:1316–1319.
   PubMed Web of Science ®Google Scholar
• Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al. 2009. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 66:1013–1022.
   PubMed Web of Science ®Google Scholar
• Meyer U. 2011. Anti-inflammatory signaling in schizophrenia. Brain Behav Immun 25:1507–1518.
   PubMed Web of Science ®Google Scholar
• Meyer U, Feldon J, Yee BK. 2009. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 35(5):959–972.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70: 663–671.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Culpepper N, Rapaport MH. 2013. C-reactive protein levels in schizophrenia. Clin Schizophr Relat Psychoses1–22. [Epub ahead of print].
   Google Scholar
• Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N, et al. 2011. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 72:1677–1684.
   PubMed Web of Science ®Google Scholar
• Monji A, Kato T, Kanba S. 2009. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63:257–265.
   PubMed Web of Science ®Google Scholar
• Monteleone P, Fabrazzo M, Tortorella A, Maj M. 1997. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71:11–17.
   PubMed Web of Science ®Google Scholar
• Morar B, Schwab SG, Albus M, Maier W, Lerer B, Wildenauer DB. 2007. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 144B:318–324.
   PubMed Web of Science ®Google Scholar
• Müller N, Schwarz M. 2006. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10:131–148.
   PubMed Web of Science ®Google Scholar
• Müller N, Schwarz MJ. 2007. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm Suppl 72:269–280.
   Google Scholar
• Müller N, Riedel M, Ackenheil M, Schwarz MJ. 2000. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J Biol Psychiatry 1:173–179.
   PubMedGoogle Scholar
• Mundo E, Altamura AC, Vismara S, Zanardini R, Bignotti S, Randazzo R, Montresor C, Gennarelli M. 2005. MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. Am J Med Genet B Neuropsychiatr Genet 132B:1–4.
   PubMed Web of Science ®Google Scholar
• Murray CJL, Lopez AD, eds. 1996. Summary: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard University Press.
   Google Scholar
• Naudin J, Mège JL, Azorin JM, Dassa D. 1996. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 20:269–273.
   PubMed Web of Science ®Google Scholar
• Nawa H, Takahashi M, Patterson PH. 2000. Cytokine and growth factor involvement in schizophrenia - support for the developmental model. Mol Psychiatry 5:594–603.
   PubMed Web of Science ®Google Scholar
• Naz M, Riaz M, Saleem M. 2011. Potential role of neuregulin 1 and TNF-alpha (-308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. Mol Biol Rep 38: 4709–4714.
   PubMed Web of Science ®Google Scholar
• Ng F, Berk M, Dean O, Bush AI. 2008. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11:851–876.
   PubMed Web of Science ®Google Scholar
• Noto C, Gadelha A, Belangero SI, Spindola LM, Rocha NP, de Miranda AS, et al. 2013. Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. J Psychiatr Res 47:467–471.
   PubMed Web of Science ®Google Scholar
• Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, et al. 2000. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci 54:419–426.
   PubMed Web of Science ®Google Scholar
• Pae CU, Chung KI, Kim JJ, Yu HS, Lee CU, Lee SJ, et al. 2004a. Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population. Psychiatr Genet 14:65–67.
   PubMed Web of Science ®Google Scholar
• Pae CU, Lee KU, Han H, Serretti A, Jun TY. 2004b. Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. Psychiatry Res 125:65–68.
   PubMed Web of Science ®Google Scholar
• Pae CU, Serretti A, Artioli P, Kim TS, Kim JJ, Lee CU, et al. 2006. Interaction analysis between 5–HTTLPR and TNFA -238/-308 polymorphisms in schizophrenia. J Neural Transm 113:887–897.
   PubMed Web of Science ®Google Scholar
• Palladino I, Salani F, Ciaramella A, Rubino IA, Caltagirone C, Fagioli S, et al. 2012. Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia. J Neuroinflammation 9:206.
   PubMed Web of Science ®Google Scholar
• Patterson PH. 2009. Immune involvement in schizophrenia and autism: Etiology, pathology and animal models. Behav Brain Res 204:313–321.
   PubMed Web of Science ®Google Scholar
• Paul-Samojedny M, Owczarek A, Kowalczyk M, Suchanek R, Palacz M, Kucia K, et al. 2013. Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFα) gene polymorphisms with paranoid schizophrenia in a Polish population. J Neuropsychiatry Clin Neurosci 25:72–82.
   PubMed Web of Science ®Google Scholar
• Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC, et al. 2012. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 46:819–824.
   PubMed Web of Science ®Google Scholar
• Pociot F, Mølvig J, Wogensen L, Worsaae H, Nerup J. 1992. A TaqI polymorphismin the human interleukin-1b (IL-1b) gene correlates with IL-1b secretion in vitro. Eur J Clin Invest 22:396–402.
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63: 801–808.
   PubMed Web of Science ®Google Scholar
• Quan N and Herkenham M. 2002. Connecting cytokines and brain: A review of current issues. Histol Histopathol 17: 273–288.
   PubMed Web of Science ®Google Scholar
• Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. 1997. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 25(2): 123–129.
   PubMed Web of Science ®Google Scholar
• Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M, et al. 2011. Dysregulation of chemo- cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 12:13.
   PubMed Web of Science ®Google Scholar
• Riedel M, Krönig H, Schwarz MJ, Engel RR, Kühn KU, Sikorski C, et al. 2002. No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci 252:232–234.
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G, et al. 2007. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 31:361–364.
   PubMed Web of Science ®Google Scholar
• Rudduck C, Beckman L, Franzén G, Jacobsson L, Lindström L. 1998. Complement factor C4 in schizophrenia. Hum Hered 35(4):223–226.
   Google Scholar
• Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. 2007. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7:46.
   PubMed Web of Science ®Google Scholar
• Saha N, Bhattacharyya SP, Tsoi WF. 1985. Serum protein markers in schizophrenia: haptoglobin, transferrin and group-specific component types. Singapore Med J 26:337–340.
   PubMedGoogle Scholar
• Santos Sória LD, Moura Gubert CD, Ceresér KM, Gama CS, Kapczinski F. 2012. Increased serum levels of C3 and C4 in patients with schizophrenia compared to eutymic patients with bipolar disorder and healthy. Rev Bras Psiquiatr 34: 119–120.
   PubMed Web of Science ®Google Scholar
• Santtila S, Savinainen K, Hurme M. 1998. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1b production in vitro. Scand J Immunol 47:195–198.
   PubMed Web of Science ®Google Scholar
• Sasayama D, Hori H, Teraishi T, Hattori K, Ota M, Iijima Y, et al. 2011a. Possible association between interleukin-1β gene and schizophrenia in a Japanese population. Behav Brain Funct 7:35.
   PubMed Web of Science ®Google Scholar
• Sasayama D, Wakabayashi C, Hori H, Teraishi T, Hattori K, Ota M, et al. 2011b. Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients. J Psychiatr Res 45:1439–1444.
   PubMed Web of Science ®Google Scholar
• Schoknecht K, Shalev H. 2012. Blood–brain barrier dysfunction in brain diseases: clinical experience. Epilepsia 53:7–13.
   PubMed Web of Science ®Google Scholar
• Schroers R, Nöthen MM, Rietschel M, Albus M, Maier W, Schwab S, et al. 1997. Investigation of complement C4B deficiency in schizophrenia. Hum Hered 47:279–282.
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Krönig H, Riedel M, Dehning S, Douhet A, Spellmann I, et al. 2006. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256:72–76.
   PubMed Web of Science ®Google Scholar
• Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al. 2002. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359:397–401.
   PubMed Web of Science ®Google Scholar
• Shcherbakova I, Neshkova E, Dotsenko V, Platonova T, Shcherbakova E, Yarovaya G. 1999. The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. Immunopharmacology 43:273–279.
   PubMed Web of Science ®Google Scholar
• Shintani F, Kanba S, Maruo N, Nakaki T, Nibuya M, Suzuki E, et al. 1991. Serum interleukin-6 in schizophrenic patients. Life Sci 49:661–664.
   PubMed Web of Science ®Google Scholar
• Shirts BH, Wood J, Yolken RH, Nimgaonkar VL. 2006. Association study of IL10, IL1beta, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: suggestive association with rs16944 at IL1beta. Schizophr Res 88: 235–244
   PubMed Web of Science ®Google Scholar
• Singh B, Bera NK, Nayak CR, Chaudhuri TK. 2009. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 47:1–5.
   PubMed Web of Science ®Google Scholar
• Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP. 2009. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 65:481–488.
   PubMed Web of Science ®Google Scholar
• Spivak B, Radwan M, Elimelech D, Baruch Y, Avidan G, Tyano S. 1989. A study of the complement system in psychiatric patients. Biol Psychiatry 26:640–642.
   PubMed Web of Science ®Google Scholar
• Spivak B, Radwan M, Brandon J, Baruch Y, Stawski M, Tyano S, et al. 1993. Reduced total complement haemolytic activity in schizophrenic patients. Psychol Med 23:315–318.
   PubMed Web of Science ®Google Scholar
• Stolp HB, Dziegielewska KM. 2009. Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol 35:132–146.
   PubMed Web of Science ®Google Scholar
• Sugai T, Kawamura M, Iritani S, Araki K, Makifuchi T, Imai C, et al. 2004. Prefrontal abnormality of schizophrenia revealed by DNA microarray: Impact on glial and neurotrophic gene expression. Ann NY Acad Sci 1025:84–91.
   PubMed Web of Science ®Google Scholar
• Sun S, Wang F, Wei J, Cao LY, Wu GY, Lu L, et al. 2008. Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population. Neurosci Lett 440:35–37.
   PubMed Web of Science ®Google Scholar
• Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T. 2006. Roles of glia-derived cytokines on neuronal degeneration and regeneration. Ann NY Acad Sci. 1088:219–229.
   PubMed Web of Science ®Google Scholar
• Tanaka KF, Shintani F, Fujii Y, Yagi G, Asai M. 2000. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res 96:75–80.
   PubMed Web of Science ®Google Scholar
• Tandon R, Keshavan MS, Nasrallah HA. 2008. Schizophrenia, “just the facts” what we know in 2008. Schizophr Res 102: 1–18.
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Sasaki T, Sakai T, Kamijima K, Fukuda R, Kunugi H, et al. 1997. Genes for interleukin-2 receptor beta chain, interleukin-1 beta, and schizophrenia: no evidence for the association or linkage. Am J Med Genet 74:338–341.
   PubMed Web of Science ®Google Scholar
• Teixeira AL, Reis HJ, Nicolato R, Brito-Melo G, Correa H, Teixeira MM, et al. 2008. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:710–714.
   PubMed Web of Science ®Google Scholar
• Turnbull AV, Rivier C. 1995. Regulation of the HPA axis by cytokines. Brain Behav Immun 9:253–275.
   PubMed Web of Science ®Google Scholar
• van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, et al. 2008. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 64:820–822.
   PubMed Web of Science ®Google Scholar
• Van der Meide PH, Schellekens H. 1996. Cytokines and the immune response. Biotherapy 8:243–249.
   PubMedGoogle Scholar
• Vuksan-Cusa B, Sagud M, Jakovljevic M, Peles AM, Jaksic N, Mihaljevic S, et al. 2012. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nord J Psychiatry [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Walkup J, Gallagher SK. 1999. Schizophrenia and the life course: national findings on gender differences in disability and service use. Int J Aging Hum Dev 49:79–105.
   PubMed Web of Science ®Google Scholar
• Wan C, La Y, Zhu H, Yang Y, Jiang L, Chen Y, et al. 2007. Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. Amino Acids 32:101–108.
   PubMed Web of Science ®Google Scholar
• Wang JF, Shao L, Sun X, Young LT. 2009. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 11:523–529.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Nunokawa A, Shibuya M, Kaneko N, Nawa H, Someya T. 2008. Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population. Eur Arch Psychiatry Clin Neurosci 258:422–427.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Someya T, Nawa H. 2010. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 64:217–230.
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, Fearon KCH, Maingay JP, Lai PBS, Ross JA. 1997. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol 273: E720–726.
   PubMed Web of Science ®Google Scholar
• Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H. 1996. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246:279–284.
   PubMed Web of Science ®Google Scholar
• Wong CT, Tsoi WF, Saha N. 1996. Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res 22:165–171.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z, et al. 2006. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 78:3571–3576.
   PubMed Web of Science ®Google Scholar
• Yang ZW, Chengappa KN, Shurin G, Brar JS, Rabin BS, Gubbi AV, et al. 1994. An association between anti- hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol Med 24:449–455.
   PubMed Web of Science ®Google Scholar
• Yarlagadda A, Hampe CS, Clayton AH. 2010. The blood brain barrier and the role of ratiometric molecular analysis in schizophrenia. Psychiatry (Edgmont) 7:20–23.
   PubMedGoogle Scholar
• Yoshida M, Shiroiwa K, Mouri K, Ishiguro H, Supriyanto I, Ratta-Apha W, et al. 2012. Haplotypes in the expression quantitative trait locus of interleukin-1β gene are associated with schizophrenia. Schizophr Res 140:185–191.
   PubMed Web of Science ®Google Scholar
• Zakharyan R, Khoyetsyan A, Arakelyan A, Boyajyan A, Gevorgyan A, Stahelova A, et al. 2010. Association of C1QB gene polymorphism with schizophrenia in Armenian population. BMC Med Genet 12:126.
   Web of Science ®Google Scholar
• Zakharyan R, Boyajyan A, Arakelyan A, Melkumova M, Mrazek F, Petrek M. 2012a. Monocyte chemoattractant protein-1 in schizophrenia: -2518A/G genetic variant and protein levels in Armenian population. Cytokine 58:351–354.
   PubMed Web of Science ®Google Scholar
• Zakharyan R, Petrek M, Arakelyan A, Mrazek F Atshemyan S, Boyajyan A. 2012b. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 80:136–142.
   PubMed Web of Science ®Google Scholar
• Zanardini R, Bocchio-Chiavetto L, Scassellati C, Bonvicini C, Tura GB, Rossi G, et al. 2003. Association between IL- 1beta -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. J Psychiatr Res 37:457–462.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. 2002. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 57:247–258.
   PubMed Web of Science ®Google Scholar
• Zhong H, Peng L, Zhu Y, Dang J, Huo Z. 2011. Association of the polymorphisms in the promoter region of tumor necrosis factor alpha and interleukin 6 genes with schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28:427–431.
   PubMedGoogle Scholar
• Zhong HJ, Peng L, Zhu YS, Dang J, Huo ZH. 2011. Association of the polymorphisms in the promoter region of tumor necrosis factor alpha and interleukin 6 genes with schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28:427–431.
   PubMedGoogle Scholar
• Zubarev OE, Klimenko VM. 2011. Elevation of proinflammatory cytokines level at early age as the risk factor of neurological and mental pathology development. Ross Fiziol Zh Im I M Sechenova 97:1048–1059.
   PubMedGoogle Scholar